Welcome to our dedicated page for ASTERA LABS SEC filings (Ticker: ALAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Astera Labs, Inc. SEC filings page for ticker ALAB provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed semiconductor company focused on rack-scale AI infrastructure, Astera Labs uses these filings to report material events, financial results, and other information relevant to investors.
Recent filings include multiple Form 8-K reports. Some of these 8-Ks furnish press releases covering quarterly financial results, described under Item 2.02, “Results of Operations and Financial Condition.” Others report material events such as Astera Labs entering into a definitive agreement to acquire aiXscale Photonics GmbH, disclosed under Item 8.01, “Other Events.” These documents link directly to the company’s public communications and provide the formal regulatory record.
Through this page, users can locate Astera Labs’ quarterly earnings information as furnished in Form 8-K, along with other current reports that explain significant developments in the business. While the examples provided reference 8-K filings, the broader filings history may also include annual reports on Form 10-K, quarterly reports on Form 10-Q, and other forms that detail the company’s financial condition, risk factors, and governance matters.
Stock Titan enhances these filings with AI-powered summaries that help explain key points from lengthy documents, such as earnings releases or transaction announcements. Real-time updates from EDGAR allow investors to see new ALAB filings as they appear, while AI-generated highlights can make it easier to understand how specific disclosures relate to Astera Labs’ rack-scale AI connectivity strategy, collaborations with hyperscalers, and acquisitions such as the aiXscale Photonics agreement.
ALAB affiliate intends to sell 33,000 shares. A Form 144 filing lists 33,000 Common shares associated with Morgan Stanley Smith Barney LLC, a proposed aggregate amount of $3,616,800.00, and indicates the securities were privately acquired from the issuer or an affiliate on 11/30/2018. The filing date is 04/01/2026 and the shares are listed for sale on NASDAQ.
ALAB proposed the sale of 170,000 shares of Common Stock under Form 144. The filing lists Morgan Stanley Smith Barney LLC, Executive Financial Services, as the filer and shows the shares were acquired on 03/21/2018 by private acquisition from issuer or an affiliate. The filing records $18,632,000.00 on the securities line and includes an anchor date of 04/01/2026.
Astera Labs Inc Schedule 13G/A amendment: The Vanguard Group reports zero beneficial ownership of Astera Labs common stock following an internal realignment that disaggregated certain subsidiaries' holdings, in accordance with SEC Release No. 34-39538.
The filing states Vanguard’s subsidiaries will report beneficial ownership separately and that Vanguard no longer is deemed to beneficially own the shares previously reported by those units.
Astera Labs filed a shelf registration on Form S-3ASR to register up to 5,578,474 shares of Common Stock for resale by selling stockholder Amazon.com NV Investment Holdings LLC. The prospectus states the company will not receive any proceeds from these resales and that the shares consist of warrants exercisable into Common Stock.
The prospectus notes 1,248,707 shares underlying the warrants were vested and exercisable as of February 28, 2026, and that percentage ownership calculations use 171,246,523 shares outstanding as of that date. The selling stockholder’s post‑offering ownership is shown assuming sale of all registered shares.
Astera Labs, Inc. director and Chief Executive Officer Mohan Jitendra reported that a living trust associated with him sold 157,500 shares of common stock in open-market transactions on March 17, 2026, under a pre-arranged Rule 10b5-1 trading plan adopted on December 1, 2025.
The sales were executed indirectly through the living trust at weighted-average prices generally between about $125 and $135 per share, in multiple tranches. After these transactions, the filing shows the living trust holding 4,531,732 shares, and it also lists additional indirect holdings in several estate planning trusts and 1,452,739 shares held directly, with Jitendra disclaiming beneficial ownership of the trust-held shares except for any pecuniary interest.
Astera Labs filer submitted a Form 144 for the resale of 281,250 shares of Common Stock, including securities acquired as RSUs on 02/15/25. The filing lists J.P. Morgan Securities LLC as broker-dealer.
The filing also discloses prior sales by the same holder: 94,971 shares sold on 02/17/2026 for $11,758,145.75.
Astera Labs, Inc. director Jack R. Lazar reported an open-market sale of 2,500 shares of Common Stock at $130.0000 per share. The transaction occurred on March 16, 2026 and was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 2, 2025.
Following this sale, Lazar directly holds 84,851 shares of Astera Labs Common Stock, so the transaction represents a small portion of his reported holdings and appears to be a routine, pre-planned disposition rather than a discretionary trade.
ALAB insider filing reports a planned resale of 2,500 RSUs and discloses a prior sale of 7,500 common shares on 03/05/2026 for $898,471.75. The Form 144 lists the RSUs as issuer-originated with an intended sale date of 02/15/2026.
Astera Labs, Inc. Chief Financial Officer Desmond Lynch filed an initial ownership report on Form 3. The filing shows he beneficially owns 0 shares of Astera Labs common stock directly following this reporting event. This is a routine disclosure of insider ownership required for company officers.
Astera Labs, Inc. director Jack R. Lazar reported selling a total of 7,500 shares of common stock in open-market transactions on March 5, 2026. The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 2, 2025.
The weighted average sale prices ranged from about $117.64 to $123.50 per share across multiple trades. After these transactions, Lazar directly holds 87,351 shares of Astera Labs common stock.